Balyasny Asset Management
PMVP icon

Balyasny Asset Management’s PMV Pharmaceuticals PMVP Stock Holding History

Balyasny Asset Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-34,147
Closed -$297K – 3042
2022
Q4 		$297K Buy
+34,147
New +$364K ﹤0.01% 1997

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Balyasny Asset Management's PMVP Position: Q1 2023 in Review

Balyasny Asset Management sold out of PMV Pharmaceuticals (PMVP) in Q1 2023, closing a stake of 34,147 shares — an estimated $297K sold.

Balyasny Asset Management first reported a position in PMVP in Q4 2022 and held it in 1 quarter. The position peaked at $297K in Q4 2022. 111 funds tracked by Wall St. Rank hold PMVP as of Q1 2023.

  • Balyasny Asset Management reported no remaining PMV Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 34,147 PMV Pharmaceuticals shares in Q1 2023, an estimated $297K.
  • Balyasny Asset Management first reported a position in PMV Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Balyasny Asset Management's PMV Pharmaceuticals position peaked at $297K in Q4 2022.
  • 111 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.